

4DMedical receives \$6.0m R&D Tax Incentive

2 September 2025

Highlights

- 4DMedical extends cash runway with \$6.0 million R&D Tax Incentive
- Including the recently announced strategic investment from Pro Medicus of \$10.0m, and the R&D Tax Incentive payment, 4DMedical's proforma cash balance as at 30 June 2025 is \$22.9m
- Further potential capital injection of up to \$22.7 million from the exercise of 41 million options (ASX:4DXOA) with an expiry date of 1 October, and at an exercise price of \$0.55
- 4DMedical's XV LVAS® technology breakthrough published in a world-leading respiratory journal, demonstrating high accuracy in predicting life-threatening pneumothorax complications resulting from bronchoscopic lung volume reduction procedures, enabling clinicians to significantly improve patient safety and outcomes in COPD treatment

Melbourne, Australia, 2 September 2025 – 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”) a global leader in respiratory imaging technology, today announces the receipt of Research and Development (R&D) Tax Incentive credits of \$6.0 million.

Additionally, the Company is pleased to announce the publication of a study in the American Journal of Respiratory and Critical Care Medicine (the “Blue Journal”), one of the world’s leading respiratory medicine journals. The study details unique functional insights delivered by XV LVAS® capable of predicting post-procedural complications in interventional procedures that are otherwise unavailable with conventional imaging.

Strengthened financial position as CT:VQ™ commercialisation commences

The Company has now received \$6.0m in R&D Tax Incentive credits. Combined with the recently announced strategic investment from Pro Medicus of \$10.0m, 4DMedical's proforma cash balance as at 30 June 2025 is \$22.9m.

Furthermore, the potential exercise of approximately 41 million options (ASX:4DXOA), with an expiry date of 1 October, and an exercise price of \$0.55, has already prompted investors to commence exercising their rights. These options have the capacity to add up to \$22.7 million to the Company's cash balance.

With this additional capital, 4DMedical is in an excellent position to execute the rollout of CT:VQ™ and continue the commercialisation of the Company's existing product suite.

Blue Journal - XV LVAS® provides unique functional insights

World-leading respiratory journal, the American Journal of Respiratory and Critical Care Medicine, published a study evaluating XV Technology® (XV LVAS®) for patients with advanced COPD undergoing bronchoscopic lung volume reduction (BLVR) treatment.

While BLVR with endobronchial valves often provides significant improvement in lung function and quality of life in severe COPD patients, pneumothorax complications occur in 26-34% of cases. Currently, no reliable method exists to predict which patients will develop this serious complication.



The research, conducted with Temple University Hospital, showed that XV LVAS® measurements combined with standard CT imaging could predict pneumothorax risk with high accuracy (AUC = 0.833, p<0.001). This non-invasive assessment can be performed before treatment to help clinicians stratify risk and make informed decisions.

Overall, the study provides compelling evidence that 4DMedical's technology can help clinicians plan care, stratify risk, and reduce complications in patients undergoing therapy for late-stage COPD. The authors of the study commented, "These findings show that XV analysis provides unique functional insights that are otherwise unavailable with conventional imaging. This approach has the potential to improve outcomes by identifying patients at highest risk of pneumothorax before valve treatment."

The full article is available online via PubMed: <https://pubmed.ncbi.nlm.nih.gov/40845326/>

4DMedical MD/CEO and Founder Andreas Fouras said:

The receipt of the R&D Tax Incentive credits, combined with the strategic investment from Pro Medicus, significantly enhances our financial position. This capital has us well positioned to push forward with our mission to deliver world-class diagnostic tools globally.

COPD remains a key focus for 4DMedical. This condition is the 4th greatest cause of death, and we are proud of our work to help match patients with a therapy that is right for them. BLVR with EBV can provide great relief, but pneumothorax can present in about 30% of cases. The results published in the Blue Journal highlight the power of our technology to provide actionable insights that directly improve patient management, while also reducing the burden of complications for health systems.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

4Dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology**® transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ™** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient



care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com

For personal use only